ProShares Ultra Nasdaq Biotechnology (BIB)
| Assets | $77.97M |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Shares Out | 1.06M |
| Dividend (ttm) | $0.88 |
| Dividend Yield | 1.13% |
| Ex-Dividend Date | Sep 24, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 20,195 |
| Open | 75.24 |
| Previous Close | 74.98 |
| Day's Range | 75.24 - 78.75 |
| 52-Week Low | 33.78 |
| 52-Week High | 79.37 |
| Beta | 1.32 |
| Holdings | 256 |
| Inception Date | Apr 8, 2010 |
About BIB
Fund Home PageThe ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is issued by ProShares.
Top 10 Holdings
152.65% of assets| Name | Symbol | Weight |
|---|---|---|
| NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA | n/a | 35.37% |
| NASDAQ BIO INDEX SWAP BNP PARIBAS | n/a | 35.09% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA | n/a | 21.34% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE | n/a | 17.24% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONAL | n/a | 15.96% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG | n/a | 8.02% |
| Amgen Inc. | AMGN | 5.32% |
| Gilead Sciences, Inc. | GILD | 5.08% |
| Vertex Pharmaceuticals Incorporated | VRTX | 4.95% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.28% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 24, 2025 | $0.18054 | Sep 30, 2025 |
| Jun 25, 2025 | $0.17058 | Jul 1, 2025 |
| Mar 26, 2025 | $0.13094 | Apr 1, 2025 |
| Dec 23, 2024 | $0.39644 | Dec 31, 2024 |
| Sep 25, 2024 | $0.15285 | Oct 2, 2024 |
| Jun 26, 2024 | $0.26476 | Jul 3, 2024 |
Performance
BIB had a total return of 45.35% in the past year, including dividends. Since the fund's inception, the average annual return has been 16.45%.
News
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
BIB: A Tactical 2 X Leveraged Biotech ETF
BIB seeks 2× the daily return of the Nasdaq Biotechnology Index, amplifying both gains and losses through leverage. A higher expense ratio reflects leverage costs and management fees; 24 bps differenc...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?
All eyes will remain on big tech this week with Microsoft, Amazon, Meta, and Apple set to report for Q2. Outlier earnings this week include - McDonald's & Boeing. During this second peak week of the Q...
Equity CEFs/ETFs: Top Picks For 2024 - Part II
In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding fac...
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...